A Closer Look at 7 Analyst Recommendations For Catalyst Pharmaceuticals
Catalyst Pharmaceuticals (NASDAQ:CPRX) has been analyzed by 7 analysts in the last three months, revealing a diverse range…
Decoding 8 Analyst Evaluations For Catalyst Pharmaceuticals
In the last three months, 8 analysts have published ratings on Catalyst Pharmaceuticals (NASDAQ:CPRX), offering a diverse range…
Decoding 7 Analyst Evaluations For Catalyst Pharmaceuticals
7 analysts have expressed a variety of opinions on Catalyst Pharmaceuticals (NASDAQ:CPRX) over the past quarter, offering a…
Jim Cramer Likes This Bank ‘Very, Very Much,’ Says Stock Is Up 7% Over Past 6 Months
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Stanley Black & Decker, Inc.
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday’s Mid-Day Session
Shares of Applied Therapeutics, Inc.
Why Catalyst Pharmaceuticals Stock Is Trading Lower
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) shares are trading lower by 13% to $14.89 Friday morning.
Catalyst Pharmaceuticals, Inc. Announces Pricing Of $150M Public Offering Of 10M Shares Of Common Stock At A Price Of $15/Share
Catalyst Pharmaceuticals, Inc. ("Catalyst" or the "Company") (NASDAQ:CPRX) announced today the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $15.00 per
Franklin Covey Shares Fall After Q1 Results, Joins Theravance Biopharma, Voyager Therapeutics And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 50 points on Friday.
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday’s Mid-Day Session
Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings.
Catalyst Pharmaceuticals Announces FIRDAPSE New Drug Application Submitted in Japan by Partner DyDo Pharma
Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with